Developer docs
API playgroundTry for free, no card

Search company profiles

Moleculin

Full company profile

uuid0002vzx

Namestring
Moleculin
Legal namestring
Moleculin Biotech, Inc.
Websiteurl
moleculin.com
Company typeenum
Public
Founded yearint
2015
Descriptiontext

Moleculin Biotech, Inc. (NASDAQ: MBRX) is a Phase 3 clinical-stage pharmaceutical company headquartered in Houston, TX (5300 Memorial Drive, Suite 950), developing a pipeline of small-molecule drug candidates for hard-to-treat tumors and viruses. The company's lead asset is Annamycin, a next-generation liposomal anthracycline engineered to eliminate the cardiotoxicity and multidrug resistance limitations of conventional anthracyclines such as doxorubicin. Annamycin has demonstrated no clinically significant cardiotoxicity across 90 patients in five completed clinical trials, even at cumulative doses exceeding conventional anthracycline limits, with independent cardiac safety review by Cleveland Clinic confirming stable mean ejection fraction. Additional pipeline assets include WP1066 (a first-in-class STAT3 immune/transcription modulator for pediatric brain tumors and adult glioblastoma, supported by 50+ peer-reviewed publications), WP1122 (a 2-deoxy-D-glucose prodrug with improved blood-brain barrier penetration for glioblastoma), and WP1220 (a topical analog for cutaneous T-cell lymphoma).

The company's pivotal MIRACLE Phase 2B/3 trial is evaluating Annamycin in combination with cytarabine (AnnAraC) in relapsed/refractory AML across nine countries (US, Spain, Italy, Poland, Czechia, Romania, Ukraine, Lithuania, and Georgia), with enrollment of the 45th subject triggering interim data unblinding expected mid-2026. The company holds FDA Fast Track, FDA Orphan Drug, EMA Orphan Drug, and FDA Rare Pediatric Disease designations across its pipeline, plus a global patent estate jointly owned with The University of Texas System extending through June 2040 across 12 jurisdictions.

Moleculin is pre-revenue with no commercialized products and reported a net loss of $33.7M for FY2025. The business model targets potential FDA/EMA approval and commercialization likely through partnership with established pharmaceutical companies rather than independent launch. Capital is sourced from public equity offerings and warrant exercises advised by Roth Capital Partners, including approximately $8.3M raised in February 2026 and $6.5M in December 2025, with $10.3M in cash and equivalents as of March 31, 2026 and a market capitalization of approximately $13.36M.

Short descriptiontext

Moleculin Biotech is a Phase 3 clinical-stage pharmaceutical company developing non-cardiotoxic anthracycline and STAT3 inhibitor drug candidates for relapsed/refractory AML, soft tissue sarcoma lung metastases, and brain tumors. The company is pre-revenue and relies on equity and warrant-based financing to advance its pipeline.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersHouston, United States
HQ citystring
Houston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical-stage oncology drugs, anthracycline drug development, acute myeloid leukemia therapy, soft tissue sarcoma treatment, STAT3 inhibitor therapeutics
Industry2 codes
PRIMARYHLAIAIAC
Rare Oncology & Hematologic Malignancy Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code1 code
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Clinical-stage oncology pharmaceuticals
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Product Revenue
TypeOne Time License
Description

Moleculin is a Phase 3 clinical stage pharmaceutical company with no current revenue. The company is focused on advancing Annamycin through clinical trials toward potential FDA approval and commercialization for the treatment of relapsed/refractory AML and soft tissue sarcoma lung metastases.

moleculin.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components2 values
Technology or R&D, Personnel
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 7 records shown
1Annamycin
Description

Lead product candidate - next-generation non-cardiotoxic anthracycline for treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma lung metastases

moleculin.com
+6 more records
Core offering1 text field

Moleculin Biotech is a Phase 3 clinical-stage pharmaceutical company developing a pipeline of proprietary drug candidates targeting hard-to-treat tumors and viruses. Its lead candidate, Annamycin, is a next-generation, non-cardiotoxic liposomal anthracycline being advanced in a pivotal Phase 2B/3 trial (MIRACLE) for relapsed/refractory acute myeloid leukemia (AML) and in Phase 1B/2 for soft tissue sarcoma lung metastases. Additional candidates include WP1066 (STAT3 inhibitor), WP1122 (glycosylation inhibitor), and WP1220 (topical p-STAT3 inhibitor for cutaneous T-cell lymphoma).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 40% composite complete remission rate in first 30 MIRACLE trial subjects vs 17-18% historical cytarabine benchmarks
+3 more records
Product overview1 text field

Moleculin Biotech is a Phase 3 clinical stage pharmaceutical company advancing a pipeline of therapeutic drug candidates addressing hard-to-treat tumors and viruses. The company's portfolio includes: Annamycin, a next-generation non-cardiotoxic anthracycline in pivotal Phase 3 trials for AML and Phase 1B/2 for soft tissue sarcoma lung metastases; WP1066, an immune/transcription modulator targeting p-STAT3 for brain tumors and pancreatic cancer; WP1122, a metabolism/glycosylation inhibitor for glioblastoma and pancreatic cancer; and WP1220, a topical treatment for cutaneous T-cell lymphoma. The lead program Annamycin is designed to avoid cardiotoxicity and multidrug resistance mechanisms that limit conventional anthracyclines.

Product and service4 records
1Annamycin
CategoryOncology drug candidate (anthracycline)
Description

A next-generation, non-cardiotoxic liposomal anthracycline drug candidate designed to treat relapsed/refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases. Demonstrates lack of cardiotoxicity across 90 patients in completed trials and avoids multidrug resistance mechanisms.

2WP1066
CategoryOncology drug candidate (STAT3 inhibitor)
Description

A first-in-class immune/transcription modulator targeting p-STAT3 and other oncogenic transcription factors while stimulating natural immune responses. In development for brain tumors (including pediatric DIPG), pancreatic cancer, and other oncology indications. Subject of over 50 peer-reviewed publications.

3WP1122
CategoryOncology drug candidate (glycosylation inhibitor)
Description

A prodrug of 2-deoxy-D-glucose (2-DG) acting as a metabolism/glycosylation inhibitor with improved cellular uptake, extended drug half-life, and enhanced blood-brain barrier penetration. In development for glioblastoma (with FDA Orphan Drug Designation) and pancreatic cancer.

4WP1220
Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-12-17
Description

Conducted positive Phase 1 clinical trial of WP1066 for treatment of pediatric recurrent malignant brain tumors in 10 children

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-12-08
Description

Research and material transfer agreement to evaluate Annamycin for treating glioblastoma multiforme, with preclinical research being conducted in mouse models under direction of Principal Investigator

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-11-12
Description

Investigator-initiated preclinical research agreement evaluating Annamycin for pancreatic cancer treatment, comparing liposomal Annamycin against Doxil and Free-doxorubicin in PDAC GEMM models

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-10-24
Description

Collaboration for Phase 1B/2 clinical trial evaluating Annamycin for third-line treatment of advanced pancreatic cancer, expected to cost approximately $1 million from 2026 to 2030

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Joint ownership of Annamycin intellectual property including patents for liposomal formulation and reconstitution methods, extending through June 2040 globally

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Independent cardiac safety review of Annamycin pooled data from 90 patients across five clinical trials, confirming no clinically significant cardiotoxicity

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Investigator-initiated Phase 2 study evaluating WP1066 in combination with radiation therapy for adult glioblastoma under Northwestern's IND application (NU 21C06)

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Jazz markets Vyxeos, an approved liposomal daunorubicin + cytarabine combination for AML — the closest direct competitor to Moleculin's AnnAraC program. Both companies target relapsed/refractory AML with liposomal anthracycline + cytarabine approaches, making Jazz the most directly comparable commercial-stage peer.

TypeDirect peer
Description

Aprea is a clinical-stage oncology company focused on hematologic malignancies including AML. Comparable to Moleculin in size, stage, and indication focus, with a similarly underexplored market cap and reliance on pivotal data readouts.

TypeDirect peer
Description

Actinium is a clinical-stage company developing targeted radiotherapies for hematologic cancers, including AML. Comparable in size, listing (NYSE American), and focus on relapsed/refractory AML — a directly overlapping clinical and commercial thesis.

TypeDirect peer
Description

Kura is a clinical-stage precision oncology company with programs in hematologic malignancies and solid tumors. Comparable in size, pipeline depth, and strategy of leveraging orphan/rare disease designations in oncology.

TypeDirect peer
Description

GlycoMimetics is a clinical-stage company developing therapies for hematologic diseases, including AML. Comparable as a small-cap clinical-stage oncology peer focused on underserved blood cancer indications.

6Syros Pharmaceuticals
TypeDirect peer
Description

Syros is a clinical-stage biopharmaceutical company developing small-molecule therapies for hematologic malignancies. Comparable in stage, size, and target indication (hematologic cancers with high unmet need).

7Bristol-Myers Squibb
TypeBroad incumbent
Description

BMS markets AML therapies including Onureg (oral azacitidine) and has established a major AML franchise. Relevant as a potential strategic acquirer/partner for late-stage AML assets like Annamycin.

TypeBroad incumbent
Description

AbbVie is a major oncology player and acquired CEO Klemp's prior company Soliton. Represents a plausible strategic acquirer profile for late-stage oncology assets like Annamycin.

TypeBroad incumbent
Description

Daiichi Sankyo is the historical pioneer of anthracycline drug development (doxorubicin/daunorubicin originator). Relevant as a benchmark for anthracycline technology ownership and a potential strategic acquirer of next-generation liposomal anthracyclines.

TypeEmerging player
Description

CNS Pharma is a clinical-stage oncology company where Moleculin's CSO Donald Picker also serves as part-time CSO. Comparable as a small-cap clinical-stage oncology peer, though CNS focuses on brain tumors (GBM) rather than AML.

Market position
Strengths3 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds14 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Moleculin

Clinical-stage oncology pharmaceuticalsmoleculin.com

Moleculin Biotech is a Phase 3 clinical-stage pharmaceutical company developing non-cardiotoxic anthracycline and STAT3 inhibitor drug candidates for relapsed/refractory AML, soft tissue sarcoma lung metastases, and brain tumors. The company is pre-revenue and relies on equity and warrant-based financing to advance its pipeline.

What Moleculin does

Moleculin Biotech, Inc. (NASDAQ: MBRX) is a Phase 3 clinical-stage pharmaceutical company headquartered in Houston, TX (5300 Memorial Drive, Suite 950), developing a pipeline of small-molecule drug candidates for hard-to-treat tumors and viruses. The company's lead asset is Annamycin, a next-generation liposomal anthracycline engineered to eliminate the cardiotoxicity and multidrug resistance limitations of conventional anthracyclines such as doxorubicin. Annamycin has demonstrated no clinically significant cardiotoxicity across 90 patients in five completed clinical trials, even at cumulative doses exceeding conventional anthracycline limits, with independent cardiac safety review by Cleveland Clinic confirming stable mean ejection fraction. Additional pipeline assets include WP1066 (a first-in-class STAT3 immune/transcription modulator for pediatric brain tumors and adult glioblastoma, supported by 50+ peer-reviewed publications), WP1122 (a 2-deoxy-D-glucose prodrug with improved blood-brain barrier penetration for glioblastoma), and WP1220 (a topical analog for cutaneous T-cell lymphoma).

The company's pivotal MIRACLE Phase 2B/3 trial is evaluating Annamycin in combination with cytarabine (AnnAraC) in relapsed/refractory AML across nine countries (US, Spain, Italy, Poland, Czechia, Romania, Ukraine, Lithuania, and Georgia), with enrollment of the 45th subject triggering interim data unblinding expected mid-2026. The company holds FDA Fast Track, FDA Orphan Drug, EMA Orphan Drug, and FDA Rare Pediatric Disease designations across its pipeline, plus a global patent estate jointly owned with The University of Texas System extending through June 2040 across 12 jurisdictions.

Moleculin is pre-revenue with no commercialized products and reported a net loss of $33.7M for FY2025. The business model targets potential FDA/EMA approval and commercialization likely through partnership with established pharmaceutical companies rather than independent launch. Capital is sourced from public equity offerings and warrant exercises advised by Roth Capital Partners, including approximately $8.3M raised in February 2026 and $6.5M in December 2025, with $10.3M in cash and equivalents as of March 31, 2026 and a market capitalization of approximately $13.36M.

Moleculin firmographics

Firmographics
Name
Moleculin
Legal name
Moleculin Biotech, Inc.
Website
https://moleculin.com
Company type
Public
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Short description
Moleculin Biotech is a Phase 3 clinical-stage pharmaceutical company developing non-cardiotoxic anthracycline and STAT3 inhibitor drug candidates for relapsed/refractory AML, soft tissue sarcoma lung metastases, and brain tumors. The company is pre-revenue and relies on equity and warrant-based financing to advance its pipeline.
Ownership category
akta.pro rank

Moleculin industry classification

Industry
Product category
Clinical-stage oncology pharmaceuticals
NAICS
Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAIAC
Rare Oncology & Hematologic Malignancy Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Clinical-stage oncology drugs
  • Anthracycline drug development
  • Acute myeloid leukemia therapy
  • Soft tissue sarcoma treatment
  • STAT3 inhibitor therapeutics

Where Moleculin is headquartered

Location

Headquarters

HQ city
Houston
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Moleculin business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel

Revenue model

  1. Pharmaceutical Product Revenue: Moleculin is a Phase 3 clinical stage pharmaceutical company with no current revenue. The company is focused on advancing Annamycin through clinical trials toward potential FDA approval and commercialization for the treatment of relapsed/refractory AML and soft tissue sarcoma lung metastases.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Moleculin product offering

Product offering

Core offering

Moleculin Biotech is a Phase 3 clinical-stage pharmaceutical company developing a pipeline of proprietary drug candidates targeting hard-to-treat tumors and viruses. Its lead candidate, Annamycin, is a next-generation, non-cardiotoxic liposomal anthracycline being advanced in a pivotal Phase 2B/3 trial (MIRACLE) for relapsed/refractory acute myeloid leukemia (AML) and in Phase 1B/2 for soft tissue sarcoma lung metastases. Additional candidates include WP1066 (STAT3 inhibitor), WP1122 (glycosylation inhibitor), and WP1220 (topical p-STAT3 inhibitor for cutaneous T-cell lymphoma).

Product overview

Moleculin Biotech is a Phase 3 clinical stage pharmaceutical company advancing a pipeline of therapeutic drug candidates addressing hard-to-treat tumors and viruses. The company's portfolio includes: Annamycin, a next-generation non-cardiotoxic anthracycline in pivotal Phase 3 trials for AML and Phase 1B/2 for soft tissue sarcoma lung metastases; WP1066, an immune/transcription modulator targeting p-STAT3 for brain tumors and pancreatic cancer; WP1122, a metabolism/glycosylation inhibitor for glioblastoma and pancreatic cancer; and WP1220, a topical treatment for cutaneous T-cell lymphoma. The lead program Annamycin is designed to avoid cardiotoxicity and multidrug resistance mechanisms that limit conventional anthracyclines.

Differentiator

Problem solved

Functional benefit

Brands

  • Annamycin: Lead product candidate - next-generation non-cardiotoxic anthracycline for treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma lung metastases
  • WP1066
  • WP1122
  • WP1220
  • AnnAraC
  • MIRACLE Trial
  • CEO Corner

Products and services

  • Annamycin A next-generation, non-cardiotoxic liposomal anthracycline drug candidate designed to treat relapsed/refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases. Demonstrates lack of cardiotoxicity across 90 patients in completed trials and avoids multidrug resistance mechanisms.
  • WP1066 A first-in-class immune/transcription modulator targeting p-STAT3 and other oncogenic transcription factors while stimulating natural immune responses. In development for brain tumors (including pediatric DIPG), pancreatic cancer, and other oncology indications. Subject of over 50 peer-reviewed publications.
  • WP1122 A prodrug of 2-deoxy-D-glucose (2-DG) acting as a metabolism/glycosylation inhibitor with improved cellular uptake, extended drug half-life, and enhanced blood-brain barrier penetration. In development for glioblastoma (with FDA Orphan Drug Designation) and pancreatic cancer.
  • WP1220

Quantifiable outcome

  • 40% composite complete remission rate in first 30 MIRACLE trial subjects vs 17-18% historical cytarabine benchmarks
  • +3 more outcomes

Companies that use Moleculin

Customer profile

Segments3 records

Ideal customer profiles3 records

Moleculin technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Moleculin partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered minor and core.

  • Aflac Cancer and Blood Disorders Center (Emory University)minorStrategic or Co-development Partner · 17 December 2025Conducted positive Phase 1 clinical trial of WP1066 for treatment of pediatric recurrent malignant brain tumors in 10 children
  • CIC biomaGUNE (Spain)minorStrategic or Co-development Partner · 8 December 2025Research and material transfer agreement to evaluate Annamycin for treating glioblastoma multiforme, with preclinical research being conducted in mouse models under direction of Principal Investigator
  • UNC-Chapel Hill (William C. Zamboni)minorStrategic or Co-development Partner · 12 November 2025Investigator-initiated preclinical research agreement evaluating Annamycin for pancreatic cancer treatment, comparing liposomal Annamycin against Doxil and Free-doxorubicin in PDAC GEMM models
  • Atlantic HealthminorStrategic or Co-development Partner · 24 October 2025Collaboration for Phase 1B/2 clinical trial evaluating Annamycin for third-line treatment of advanced pancreatic cancer, expected to cost approximately $1 million from 2026 to 2030
  • The University of Texas SystemcoreStrategic or Co-development PartnerJoint ownership of Annamycin intellectual property including patents for liposomal formulation and reconstitution methods, extending through June 2040 globally
  • Cleveland CliniccoreStrategic or Co-development PartnerIndependent cardiac safety review of Annamycin pooled data from 90 patients across five clinical trials, confirming no clinically significant cardiotoxicity
  • Northwestern UniversityminorStrategic or Co-development PartnerInvestigator-initiated Phase 2 study evaluating WP1066 in combination with radiation therapy for adult glioblastoma under Northwestern's IND application (NU 21C06)

Scale indicators8 records

Expansion highlights6 records

Moleculin competitors and assessment

Company assessment

Direct peers

  • Jazz Pharmaceuticals: Jazz markets Vyxeos, an approved liposomal daunorubicin + cytarabine combination for AML — the closest direct competitor to Moleculin's AnnAraC program. Both companies target relapsed/refractory AML with liposomal anthracycline + cytarabine approaches, making Jazz the most directly comparable commercial-stage peer.
  • Aprea Therapeutics: Aprea is a clinical-stage oncology company focused on hematologic malignancies including AML. Comparable to Moleculin in size, stage, and indication focus, with a similarly underexplored market cap and reliance on pivotal data readouts.
  • Actinium Pharmaceuticals: Actinium is a clinical-stage company developing targeted radiotherapies for hematologic cancers, including AML. Comparable in size, listing (NYSE American), and focus on relapsed/refractory AML — a directly overlapping clinical and commercial thesis.
  • Kura Oncology: Kura is a clinical-stage precision oncology company with programs in hematologic malignancies and solid tumors. Comparable in size, pipeline depth, and strategy of leveraging orphan/rare disease designations in oncology.
  • GlycoMimetics: GlycoMimetics is a clinical-stage company developing therapies for hematologic diseases, including AML. Comparable as a small-cap clinical-stage oncology peer focused on underserved blood cancer indications.
  • Syros Pharmaceuticals: Syros is a clinical-stage biopharmaceutical company developing small-molecule therapies for hematologic malignancies. Comparable in stage, size, and target indication (hematologic cancers with high unmet need).

Broad incumbents

  • Bristol-Myers Squibb: BMS markets AML therapies including Onureg (oral azacitidine) and has established a major AML franchise. Relevant as a potential strategic acquirer/partner for late-stage AML assets like Annamycin.
  • AbbVie: AbbVie is a major oncology player and acquired CEO Klemp's prior company Soliton. Represents a plausible strategic acquirer profile for late-stage oncology assets like Annamycin.
  • Daiichi Sankyo: Daiichi Sankyo is the historical pioneer of anthracycline drug development (doxorubicin/daunorubicin originator). Relevant as a benchmark for anthracycline technology ownership and a potential strategic acquirer of next-generation liposomal anthracyclines.

Emerging players

  • CNS Pharmaceuticals: CNS Pharma is a clinical-stage oncology company where Moleculin's CSO Donald Picker also serves as part-time CSO. Comparable as a small-cap clinical-stage oncology peer, though CNS focuses on brain tumors (GBM) rather than AML.

Market position

Strengths3 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Moleculin social profiles

Digital presence

Moleculin financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Moleculin leadership team

Management profile

Number of profiles

Profiles5 records

Moleculin funding detail

Funding detail

Funding overview

Funding rounds14 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Moleculin M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Moleculin

What does Moleculin do?

Moleculin Biotech is a Phase 3 clinical-stage pharmaceutical company developing a pipeline of proprietary drug candidates targeting hard-to-treat tumors and viruses. Its lead candidate, Annamycin, is a next-generation, non-cardiotoxic liposomal anthracycline being advanced in a pivotal Phase 2B/3 trial (MIRACLE) for relapsed/refractory acute myeloid leukemia (AML) and in Phase 1B/2 for soft tissue sarcoma lung metastases. Additional candidates include WP1066 (STAT3 inhibitor), WP1122 (glycosylation inhibitor), and WP1220 (topical p-STAT3 inhibitor for cutaneous T-cell lymphoma).

Is Moleculin a public or private company?

Moleculin is a public company. It is classified as public and is currently operating.

When was Moleculin founded?

Moleculin was founded in 2015. It employs 11 to 50 people.

Where is Moleculin based?

Moleculin is headquartered in Houston, United States, in the North America region.

How does Moleculin make money?

One revenue line is on record: pharmaceutical Product Revenue.

Who are Moleculin's main competitors?

Direct peers on record are Jazz Pharmaceuticals, Aprea Therapeutics, Actinium Pharmaceuticals, Kura Oncology, GlycoMimetics and Syros Pharmaceuticals. Broad incumbents are Bristol-Myers Squibb, AbbVie and Daiichi Sankyo. CNS Pharmaceuticals is listed as an emerging player.

Does Moleculin have an API?

No public API is recorded for Moleculin.

What industry is Moleculin in?

Moleculin's product category is Clinical-stage oncology pharmaceuticals. Its primary akta.pro industry code is HLAIAIAC, Rare Oncology & Hematologic Malignancy Therapies, with a secondary code of HLAIAAAD, Immunology & Inflammation Pharmaceuticals. Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TradingViewMoleculin Biotech Wins Korean Patent Allowance for Annamycin Reconstitution MethodMoleculin Biotech received a South Korean patent allowance for its method of reconstituting liposomal Annamycin. The allowance covers application No. 10-2022-7000486, extending IP protection across formulation, reconstitution, and lung-targeted therapies. The patent expansion coincides with the company's pivotal Phase 2/3 MIRACLE trial evaluating Annamycin with cytarabine for relapsed or refractory AML.TradingViewMoleculin Biotech, Inc. (MBRX) Secures Korean Patent Allowance for AnnamycinSouth Korea's Ministry of Intellectual Property granted Moleculin Biotech a patent covering reconstitution of liposomal Annamycin. The company's portfolio spans more than 20 jurisdictions, and the allowance adds protection in another market without disclosing financial terms or commercial impact.TradingViewMoleculin Biotech, Inc. (MBRX) Reports 43% and 36% Remission Rates in Interim TrialMoleculin Biotech reported interim remission rates of 43% and 36% in two Annamycin arms versus 12% with placebo in its Phase 2/3 AML trial. The Data Monitoring Committee recommended continuing the study without amendment. A second interim analysis is expected in early 2027.TradingViewMoleculin Biotech Completes MIRACLE Part A Dosing; Data Readout on Track for Q1 2027Moleculin Biotech completed dosing in Part A of its MIRACLE trial for AnnAraC in relapsed or refractory AML, with 90 randomized patients. Comprehensive data readout is expected in Q1 2027 to inform dose selection for Part B. The final population is expected to include a 50/50 split between patients who failed 7+3 and venetoclax-based regimens.TradingViewMoleculin Biotech, Inc. (MBRX) Completes Part A Enrollment; Full Data Readout Planned Q1 2027Moleculin Biotech completed Part A enrollment in its Phase 2/3 MIRACLE trial of Annamycin plus HiDAC for relapsed/refractory AML, with encouraging interim efficacy. A full 90-patient Part A data readout is planned for Q1 2027, pending financing, and the company aims to advance to pivotal Part B.The future of tradingMoleculin Biotech grants CFO Jonathan Foster 260,000 stock options and 260,000 restricted stock unitsMoleculin Biotech granted CFO Jonathan Foster 260,000 stock options and 260,000 restricted stock units on October 15, 2026. The grant was published via EDGAR on October 16, 2026.Seeking AlphaMoleculin announces 1-for-20 reverse stock split, shares slide (MBRX:NASDAQ)Moleculin Biotech announced a 1-for-20 reverse stock split effective October 20, 2026. Shares fell over 16% in pre-market trading, with the stock trading at $0.29, down 21.62% from the previous close of $0.37.TradingViewMoleculin announces 1-for-20 reverse stock split, shares slideMoleculin Biotech announced a 1-for-20 reverse stock split effective October 20, 2026, reducing outstanding shares from about 20.9 million to nearly 1.05 million. Shares fell over 16% in pre-market trading, with no change in par value and no fractional shares issued.TradingViewAnnamycin Turns “Cold” Pancreatic Tumors “Hot” in New Preclinical Data Presented at AACRMoleculin Biotech presented preclinical data at AACR showing Annamycin's antitumor activity in pancreatic cancer is partially mediated by CD8+ T cells. The finding suggests Annamycin may turn immunologically cold tumors hot, supporting combination approaches. The data are preclinical and not predictive of human results.TradingViewMoleculin Biotech: Preclinical Data Suggest Annamycin’s Pancreatic Activity Involves CD8+ T CellsMoleculin Biotech presented preclinical data at the AACR Pancreatic Cancer Conference showing Annamycin's antitumor activity in pancreatic cancer is partially mediated by CD8+ T cells. The data suggest Annamycin may convert immunologically cold tumors to hot, enabling immune attack. Annamycin is not in clinical development for pancreatic cancer.